Mutated LEMD1 Antigen Vaccine for Tumor Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer vaccines face limitations due to poor antigen expression in vivo, necessitating the development of safe and effective vaccines that can induce immune responses and treat or prevent cancer by targeting LEMD1, a protein associated with cancer cells.
Innovation Solution
Nucleic acid molecules encoding specific sequences of the LEMD1 protein or its fragments are used to create vaccines, which can be incorporated into plasmids or viral vectors, and administered with adjuvants to induce immune responses against LEMD1-expressing cancer cells, potentially combined with immune checkpoint inhibitors to enhance efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing vaccines targeting tumor cell antigens are used, then they are administered to patients, but they fail to induce effective immune responses due to poor antigen expression in vivo
Solution Approach 1:
The patent applies parameter changes by modifying the antigen sequence to create a consensus LEMD1 antigen with optimized immunogenic properties. The consensus sequence is derived from multiple LEMD1 variants and engineered to have enhanced stability and immunogenicity while maintaining tumor-reactivity, thereby improving antigen expression and immune response induction
Solution Approach 2:
The patent employs composite materials by formulating the LEMD1 antigen with adjuvants and delivery systems to create a composite vaccine formulation. This composite approach enhances antigen stability, expression levels, and immunogenicity, overcoming the limitation of poor antigen expression when using the antigen alone
2Reliability
If standard cancer treatments are used, then they can treat advanced cancers, but they cause significant toxicity and side effects
Solution Approach 1:
The patent applies segmentation by targeting a specific tumor-associated antigen (LEMD1) rather than using non-specific cytotoxic treatments. This targeted approach segments the therapeutic action to affect only LEMD1-expressing tumor cells, spares normal tissues, and reduces systemic toxicity while maintaining cancer treatment effectiveness
Solution Approach 2:
The patent uses the LEMD1 antigen as an intermediary to mediate the immune response against tumor cells. Instead of direct cytotoxicity, the antigen serves as a bridge to activate the patient's own immune system, resulting in more selective and less toxic cancer treatment
3Reliability
If LEMD1 is targeted as a cancer antigen, then it can induce immune responses against tumor cells, but immune tolerance to LEMD1 must be broken to achieve efficacy
Solution Approach 1:
The patent applies preliminary action by using adjuvants and delivery systems that pre-condition the immune system before antigen presentation. These preliminary components activate immune cells and create a pro-inflammatory environment that breaks tolerance and primes the immune system to respond to the LEMD1 antigen
Solution Approach 2:
The patent introduces adjuvants and delivery systems as intermediaries to facilitate the breaking of immune tolerance. These intermediaries mediate between the LEMD1 antigen and the immune system, providing the necessary signals to overcome tolerance and induce effective anti-tumor immune responses
Data Source
AI summary
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen are disclosed. Methods of treating a subject with a LEMD1-expressing tumor and methods of preventing a LEMD1-expressing tumor are disclosed. Mutated consensus LEMD1 antigen is disclosed.